Clinical response during the IP
REMISSION, DISEASE
In the overall ITT population, all endpoints evaluated were achieved and sustained by numerically more patients treated with abatacept + MTX versus those treated with abatacept placebo + MTX. SDAI remission at IP week 24 was achieved by 22% (100/451) of patients receiving abatacept + MTX and 13% (40/301) receiving abatacept placebo + MTX, and of these patients, 56% (56/100) and 43% (17/40), respectively, also achieved sustained SDAI remission at IP weeks 40 and 52 (Fig. Patients with IP week 24 response who achieved weeks 40 and 52 responses. ABA, abatacept; DAS28 (CRP), Disease Activity Score in 28 joints using C-reactive protein; IP, induction period; MTX, methotrexate; PBO, placebo; SDAI, Simplified Disease Activity Index. 